Potential strategies to avoid progestogen-induced premenstrual disorders

Menopause International

Volumn 18, Issue 2, 2012, Pages 73-76

  Baker, Lucy J ^a   O'brien, P M S ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

premenstrual disorder; Progestogen; side effects; treatment

Indexed keywords

ESTROGEN; GESTAGEN; LEVONORGESTREL; SEROTONIN UPTAKE INHIBITOR;

BREAKTHROUGH BLEEDING; CLINICAL PRACTICE; ENDOMETRIOSIS; ENDOMETRIUM; HEALTH PRACTITIONER; HUMAN; ORAL CONTRACEPTION; PREMENSTRUAL SYNDROME; REVIEW;

CONTRACEPTIVES, ORAL, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; PROGESTINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84861539807     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2012.012016     Document Type: Review

References (32)

1. Rapkin AJ, Winer SA. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin Pharmacother 2008; 9: 1–17
2. Bjorn I, Bixo M, Nojd KS,, et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002; 16: 1–8
3. Wyatt K, Dimmock P, Jones P,, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323: 776–80
4. Kirkham C, Reid RL, Hahn PM,, et al. A randomized, double blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol 1991; 78: 93–97
5. Hammarback S, Backstrom CT, Holst J,, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential oestrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecologo Scand 1985; 65: 393–397
6. Henshaw C, Foreman D, Belcher J,, et al. Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy? J Psychosom Obstet Gynecol 1996; 17: 21–28
7. Royal College of Obstetricians and Gynaecologists. Premenstrual Syndrome. Management. Green-top Guideline 48. RCOG Press, 2007. See http://www.rcog.org.uk/guidelines ( last checked 1 April 2012)
8. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Women's Ment Health 2006; 9: 41–49
9. Pearlstein TB, Bachmann GA, Zacur HA,, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21
10. Rapkin AJ. Yaz in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53: 729–41
11. Wyatt KM, Dimmock PW, Ismail KM,, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004; 111: 585–93
12. Leather AT, Studd JW, Watson NR,, et al. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13: 48–55
13. Sagsveen M, Farmer J, Prentice A,, et al. Gonadotrophin- releasing analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; (4):CD001297
14. Leather A, Studd J, Watson NR,, et al. The prevention of bone loss in young women treated with GnRH analogues and add back estrogen therapy. Obstet Gynecol 1993; 81: 104–107
15. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/ progestin. J Clin Endocrinol Metab 1991; 72: 252A–252F
16. Mezrow G, Shoupe D, Spicer D,, et al. Depot leuprolide acetate with estrogen and progestin add back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932–937
17. Schmidt PM, Nieman LK, Danaceau MA,, et al. Differential behavioral effects of gonadal hormones in women with and without premenstrual syndrome. N Eng J Med 1998; 338: 209–16
18. Magos AL, Brincat M, Studd JWW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J 1986; 292: 1629–33
19. Smith RN, Studd JW, Zamblera D,, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475–84
20. Watson NR, Studd JWW, Savvas M,, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 8665: 730–732
21. Magos AL, Brewster E, Singh R,, et al. The effects of norethisterone in postmenopausal women on estrogen therapy: a model for the aetiology of premenstrual syndrome. Br J Obstet Gynaecol 1986; 93: 1290–6
22. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997; 3: 159–71
23. Grady-Weliky TA. Clinical practice. premenstrual dysphoric disorder. N Engl J Med 2003; 348: 433–438
24. Dimmock PW, Wyatt KM, Jones PW,, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356: 1131–6
25. Bethea CL, Lu NZ, Gundlah C,, et al. Diverse actions of ovarian steroids in the serotonin neural systems. Front Neuroendocrinol 2002; 23: 41–100
26. Rubinow DR, Hoban MC, Grover GN,, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5–11
27. Sturdee D. Levonorgestrel intrauterine system for endometrial protection. Menopause Int 2006; 12: 1–3
28. Atsma F, Bartelink ML, Grobbee DE,, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265–79
29. Casson P, Hahn P, VanVugt DA,, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 99–102
30. Cronje WH, Vashisht A. Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19: 2152–5
31. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105–109
32. O’Brien PM, Backstrom T, Brown C,, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Women's Ment Health 2011; 14: 13–21